Introduction: Factor VIII (FVIII) or factor IX (FIX)-deficient haemophilic patients display deficits in platelet and fibrin deposition under flow detectable in microfluidics. Compared to fibrin generation, decreased platelet deposition in haemophilic blood flow is more easily rescued with recombinant factor VIIa (rFVIIa), whereas rFVIIa requires FXIIa participation to generate fibrin when tissue factor (TF) is absent. Aims: Perfusion of haemophilic whole blood (WB) over collagen/TF surfaces was used to determine whether rFVIIa/TF was sufficient to bypass poor FIXa/FVIIIa function in blood from patients with haemophilia A and B. Methods: Whole blood treated with high-dose corn trypsin inhibitor (40 lg mL
Introduction
Haemophilia A and B are X-linked genetic disorders resulting in deficiencies in coagulation factor VIII (FVIII) or factor IX (FIX), respectively [1] . These deficiencies cause a wide range of bleeding phenotypes depending on severity [2] [3] [4] [5] . Current treatment strategies for patients with haemophilia include clotting factor replacement or bypass therapies. Bypass therapies such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa) were developed to treat haemophilic patients with inhibitors [6] . Although rFVIIa is approved, its mechanism of action is complex [7, 8] . Past work has indicated that rFVIIa can exploit tissue factor (TF) to function and may outcompete endogenous FVII for TF [9, 10] . Additional studies indicate that rFVIIa can also bind cellular surface to generate FXa independent of TF [11] [12] [13] [14] [15] . The cellular mechanism of FVIIa is well supported in the literature and motivates the development of rFVIIa mutants that have less sensitivity to TF as a cofactor (and potentially less thrombotic risk).
Microfluidic studies can help elucidate the roles of intrinsic tenase, extrinsic tenase and rFVIIa under flow. In vitro models with perfusion of FVIII-deficient blood resulted in decreased platelet aggregation and fibrin formation at low shear conditions [16] [17] [18] . The extrinsic pathway is unable to completely mitigate deficits in haemophilia A and B, possibly because TF expression varies greatly in human tissues [19, 20] . Bleeding in haemophilia is common in the joints where TF expression is considered to be low [20] . The contribution of FXa and thrombin stemming from residual intrinsic tenase in various TF-laden backgrounds has not been studied extensively. Previous studies only assessed severe cases of human FVIII or FIX deficiency (<1%) often with FXIIa function uncontrolled or blood from mice deficient in FVIII or FIX [17, 18, 21] . Few have examined how milder deficiencies in FVIII or FIX levels affect platelet adherence and fibrin formation in the presence of bypass therapy and surface TF [22] .
Previously, we have developed a contact pathwaydriven microfluidic model (no exogenous TF) that evaluated the role of FVIII or FIX in patients with congenital bleeding disorders [23, 24] . Furthermore, we previously observed that rFVIIa enhances platelet adhesion but not fibrin production when contact pathway is strongly inhibited, suggestive of low-level generation of thrombin by rFVIIa on platelets (in the absence of TF) [24] . In Li et al., we also describe how FXIIa activity can work with rFVIIa to generate fibrin. In this study, we aimed to unify our previous two studies and establish the role of wall-presented TF and rFVIIa in the regulation of thrombus formation. We measured healthy or haemophilic whole blood (WB) perfusion over collagen type I surfaces bearing TF low or TF high at a venous wall shear rate of 100 s
À1
. This study confirms that FIXa/FVIIIa is required for fibrin generation under healthy WB flow, even when TF is abundant at the wall.
Materials and methods

Blood collection and patient recruitment
Blood was drawn from healthy donors (n = 7) and patients with haemophilia (n = 10) under Internal Review Board approval of the University of Pennsylvania and informed consent. Patient data were collected (Table 1) . Residual FVIII and FIX activity was also measured. Healthy donors were self-reported free of oral medication for 7 days and abstained from alcohol 48 h prior to blood donations. WB was drawn into 40 lg mL À1 CTI (Haematologic Technologies, Essex Junction, VT, USA).
Preparation of TF-bearing collagen surfaces
Glass slides were first functionalized with Sigmacote (Sigma, St. Louis, MO, USA) to create a hydrophobic surface. Acid-insoluble equine type I collagen (ChronoPar, Chrono-log, Havertown, PA, USA) was diluted to 800 lg mL À1 in isotonic glucose solution (Chronopar) and introduced into patterning device (250 lm by 1 cm) [25, 26] , respectively, as previously measured [27] . In all experiments, TF-bearing collagen surfaces were incubated for 30 min with no flow and then washed with 5 lL of 0.5% bovine serum albumin (BSA) in HBS. This singlechannel patterning device was then removed to allow placement of microfluidic flow.
Extrinsic pathway-triggered microfluidic flow assay on TF-bearing collagen surfaces An eight-channel microfluidic device was fabricated, and its dimensions and operations were previously described [25, 28] . Blood samples were treated with fluorescently conjugated non-function-blocking antiCD41a antibody (clone VI-PL2, 0.125 lg mL À1 final concentration; Becton Dickson, Franklin Lakes, NJ, Platelet and fibrin fluorescent intensities were imaged at 60-s intervals for 900 s using IMAGEJ software (NIH) with background subtraction and region of interest analysis conducted as previously described [25, 26] . Full channel occlusion of the 60-lm-high channel (indicated as 100% OCC) was detected during the microfluidic experiments with healthy WB when the flow stopped. Blood from patients with haemophilia (no added rFVIIa) typically never reached full occlusion in the 900-s assays. Statistical comparisons (two-tailed student's t-test for n = number of individual blood samples) of platelet and fibrin deposition were made for haemophilia cohorts relative to a healthy cohort (seven donors) at the 900-s endpoint. Statistical comparisons were also made for responses of each rFVIIa-treated blood sample, internally normalized to its response with no added rFVIIa, via clotting tests run side by side on the microfluidic devices.
Results
Surface-triggered extrinsic pathway under flow does not rescue platelet adherence or fibrin generation at 1-3% factor activity
In our previous work, we reported no fibrin formation under flow in two FVIII-deficient patients (1-3% factor level) when high-CTI-anticoagulated haemophilic blood was perfused over collagen surfaces (no exogenous surface TF) [24] . We now sought to evaluate the haemostatic potential of surface TF to rescue such deficits through perfusion of haemophilic WB over collagen surfaces bearing TF low or TF high . Aggregate analysis of high-CTI-inhibited WB from one severely VIII-deficient patient (#62:3% factor level), one severely FIX-deficient patient (#29:<1% factor level) and one moderately FVIII-deficient patient (#69:2% factor level) produced no detectable levels of fibrin at 900-s assay endpoint ( standard deviation of six clotting events measured in 60-s intervals over 15 min for three distinct patients with haemophilia (red) or 18 clotting events measured in 60-s intervals over 15 min for seven distinct healthy subjects (black). Aggregate haemophilic data were from one severely VIII-deficient patient (#62:3% factor level), one severely factor IX-deficient patient (#29:<1% factor level) and one moderately factor VIII-deficient patient (#69:2% factor level).
(**P < 0.01, *P < 0.05, ns: non-significant). )-treated haemophilic WB on collagen surfaces alone (no TF) from four patients at 3-10% residual factor levels did not result in any fibrin accumulation by 900 s [24] . Additionally, similar to the 1-3% factor activity group, small non-statistically significant deficits in platelet adhesion on TF collagen surfaces were again observed at 900 s (Fig. 2a & c: red lines, ns). These results indicate that engagement of the intrinsic tenase (FIXa/FVIIIa ? FXa) in combination with FXa production from TF/FVIIa on TF high collagen surfaces was sufficient to produce low amounts of fibrin (Fig. 2b & d: red lines) .
Platelet adhesion is rescued by the extrinsic pathway on TF low collagen surfaces, while fibrin formation is fully restored on TF low and TF high collagen surfaces at >14% factor activity Platelet deposition from WB of two severely FVIIIdeficient patients (#63 & #70) recently treated with therapy to increase their FVIII levels to 32% and 24%, respectively, and one mildly FVIII-deficient patient (#67:18% factor level) was commensurate with healthy blood until occlusion and then decreased in comparison with the platelet deposition from healthy controls on TF high collagen surfaces at the assay endpoint (Fig. 3c : red line, P < 0.05), an effect not apparent with TF low collagen surfaces (Fig. 3a: red line, ns). We observed no statistically significant deficits in fibrin production at >14% factor activity at 900 s in the presence of either surface concentration WB inhibited with 40 lg mL À1 CTI was perfused over TF high -bearing collagen surfaces at 100 s À1 . Lines with shaded traces and points are the mean and standard deviation of eight clotting events measured in 60-s intervals over 15 min for four distinct patients with haemophilia (red) or 18 clotting events measured in 60-s intervals over 15 min for seven distinct healthy subjects (black). Aggregate haemophilic data from two severely FIX-deficient patients WB (#64 & #65) recently treated with therapy to increase their factor IX (FIX) levels to 14% and 6%, respectively, a moderately factor VIII-deficient patient (#68:6% factor level) and a moderately FIX-deficient patient (#71:5% factor level; **P < 0.01, *P < 0.05, ns: non-significant).
of TF on collagen when compared to healthy donors ( Fig. 3b & d: red lines, ns) . This is in contrast to our previous work where two mildly FVIII-deficient patients (15% factor level) generated negligible to low amounts of fibrin with perfusion of CTI (40 lg mL
À1
)-treated haemophilic blood on collagen surfaces (no surface TF) [24] . Time to fibrin initiation and total fibrin accumulation was fully restored with TF high collagen surfaces (Fig. 3d: red line, ns) .
In examining total platelet and fibrin accumulation under flow at 15 min for all cohorts, platelet and fibrin accumulation was highly defective for blood from patients with 1-3% normal factor levels when compared to healthy blood (Fig. 4A-D : P < 0.01 [TF low collagen], P < 0.05 [TF high collagen]). High levels of surface TF do not rescue fibrin formation at 1-3% factor levels in patients with haemophilia ( Fig. 4d: 1-3% , P < 0.01) whose blood generated essentially no fibrin.
Exogenous rFVIIa significantly enhances platelet deposition on TF high collagen surfaces, but non-significantly increases fibrin accumulation at 20 nM on TF low or TF high collagen at 1-3% factor activity Perfusion of WB from a severely FIX-deficient patient (#29, <1% FIX) showed negligible fibrin accumulation that increased to healthy donor levels with 20 nM exogenous rFVIIa on TF low or TF high collagen (Fig. 5b: black, grey and red lines). Addition of 20 nM rFVIIa also enhanced platelet deposition to healthy donor levels at either TF concentration (Fig. 5a , c: red lines). Figure 5 demonstrated in a single severe haemophilic patient blood sample that rFVIIa enhanced platelet and fibrin production in a dose-dependent manner, especially at the high TF surface, to levels approaching the healthy donor cohort baseline.
The effect of exogenously added rFVIIa was tested on all patients examined in Figs 1-4 . At 1-3% factor level, exogenous 20 nM rFVIIa significantly increased final platelet accumulation vs. 0 nM rFVIIa (Fig. 6c: 1-3% , P < 0.05) to levels commensurate with that observed with untreated healthy blood on TF high collagen. Final fibrin accumulation with 20 nM rFVIIa was also increased vs. 0 nM rFVIIa and trended towards statistical significance on TF high collagen surfaces at 1-3% factor activity ( Fig. 6d: 1-3% P = 0.0715). For the severe cohort (1-3% factor level) of three donors, the mean fold enhancement of fibrin deposition at 20 nM rFVIIa (with each signal internally normalized by the 0 nM rFVIIa condition) was statistically significant (4.6 AE 2.1-fold over baseline at high TF, P < 0.05). Also, for high TF surfaces (Fig. 6d) , the average fibrin deposition with 20 nM rFVIIa treatment for the severe cohort (n = 3) was not statistically different (P = 0.14) from that observed for the healthy cohort (n = 7), indicating pharmacological correction of the defect. With WB inhibited with 40 lg mL À1 CTI was perfused over TF high -bearing collagen surfaces at 100 s À1 . Lines with shaded traces and points are the mean and standard deviation of six clotting events measured in 60-s intervals over 15 min for three distinct patients with haemophilia (red) or 18 clotting events measured in 60-s intervals over 15 min for seven distinct healthy subjects (black). Aggregate haemophilic data from two severely factor VIII-deficient patients (#63 & #70) recently treated with therapy to increase their FVIII levels to 32% and 24%, respectively, and one mildly FVIII-deficient patient (#67:18% factor level). (*P < 0.05, ns: non-significant).
increasing rFVIIa supplementation, healthy WB also displayed statistically significant increases in platelet and fibrin deposition on TF low or TF high collagen surfaces ( Fig. 6a -d: healthy, P < 0.05). Final platelet or fibrin accumulation on TF high -bearing collagen surfaces at 100 s À1 measured by platelet or fibrin fluorescence at t = 15 min or just prior to full channel occlusion. All data are ordered into three factor level categories (1-3%, 3-14% and >14%) and compared to mean healthy subject final platelet or fibrin accumulation. Error bars are the standard deviation of six clotting events for each factor level category and 18 clotting events for seven healthy subjects. (**P < 0.01, *P < 0.05, ns: non-significant). TF high /collagen surfaces at 100 s À1 were used to evaluate platelet deposition and fibrin formation in patients with haemophilia. A broad cohort of patients were tested representing a large spectrum of clinical phenotypes of haemophilia A or B (Table 1) . Under these ex vivo haemodynamic conditions, we observed significantly decreased platelet deposition and fibrin formation at 900 s on TF low and TF high collagen surfaces in haemophilic samples with 1-3% residual factor levels ( Fig. 1a-d) . Taken together, these results indicate that in healthy blood clotting under flow conditions over TF, most factor Xa comes from the intrinsic tenase (FIXa/FVIIIa) even when some FXa can be initially generated by the extrinsic tenase TF/FVIIa (Figs 1-4,  7) .
Discussion and conclusion
Healthy blood responded to higher TF surfaces with a faster occlusion time and with more fibrin made (Fig. 1) , whereas severely deficient blood (1-3% clotting factor) was largely insensitive to TF level and never reached full occlusion. For patients with moderate haemophilia (3-14% clotting factor), the blood displayed some ability to utilize surface TF and generate some fibrin with increased platelet deposition, albeit less than healthy blood. For patients with mild deficiency (>14% clotting factor), the blood performs in a manner approaching that of healthy blood in this microfluidic assay, at either low or high TF levels.
With the intrinsic tenase severely attenuated as in the case of severe FVIII or FIX deficiency, surface TFtriggered coagulation failed to produce adequate levels of thrombin for detectable fibrin formation (Fig. 1b,  d , P < 0.01). At high surface TF concentrations of~2 TF molecules per lm 2 as measured in a prior study [27] , the extrinsic tenase could not support fibrin formation out to 900 s when critical residual clotting factor activity was <3% (Fig. 1d, P < 0.01) .
We also assessed the role of rFVIIa in platelet deposition and fibrin formation under flow in haemophilic and healthy WB samples. Results from a patient with severe haemophilia indicate that rFVIIa amplifies platelet deposition and fibrin formation in the presence of surface TF (Fig. 5) . Analysis of final platelet and fibrin deposit size in the presence of exogenous rFVIIa indicates enhancement of platelet and fibrin accumulation at 1-3% normal factor levels (Fig. 6) . The number (mass) of platelets on the surface is strongly correlated with the height of the clot. Importantly, rFVIIa increases the growth rate and height of the platelet mass. Fibrin accumulation commences after platelet accumulation has begun, indicative of a protective low shear zone for fibrin polymerization within the platelet deposit.
Numerous and complex couplings exist between platelets, TF, thrombin and fibrin. In general for cence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 40 lg mL À1 CTI was perfused on TF high -bearing collagen surfaces at 100 s À1 . All data are ordered into three factor level categories (1-3%, 3-14% and >14%) compared to mean healthy subject final platelet or fibrin accumulation. Error bars are the standard deviation of six clotting events for each factor level category and 18 clotting events for seven healthy subjects. N indicates the number of patients or donors (**P < 0.01, *P < 0.05, ns: non-significant).
healthy blood, we have found platelet deposition to be sensitive to thrombin, particularly when comparing zero thrombin to low thrombin, where thrombin can enhance platelet deposition by~2-or 3-fold. However, the collagen used in the experiment is potent and evokes a reasonable amount of platelet deposition even for severe haemophilic blood. In contrast, fibrin deposition with healthy blood is extremely responsive to thrombin production and can increase >10-to 20-fold with TF. Based on a separate study [29] , we conclude fibrin formation is more dependent on TF (and thrombin) and somewhat less dependent on platelets during the first 500 s of clotting, once the first layer of platelets have deposited on the surface. For healthy blood, the first layer of platelets is largely sufficient for thrombin production by surface TF during the first 500 s. After 500 s, thrombin production is more platelet dependent as platelets facilitate thrombin feedback activation of FXIa (potentially via polyphosphate [27] ). Such pathways remain to be studied in haemophilic blood in microfluidic assay.
Through flow experiments, we sought to better understand the relation between the nonlinear thrombin kinetics in a tube assay (i.e. initiation, amplification, propagation) and fibrin formation under flow. In our earlier work [23] , a PTT clotting time of >40 s was fully predictive of poor fibrin formation under flow over collagen (no TF). Yet, recent measurements of thrombin generation during WB flow (using TAT assay) indicate a different kinetics may be in place under flow where thrombin flux increases linearly with time to about 0.5 9 10
À12 nmole lm
À2
-s by 500 s while dense intraclot fibrin is a powerful inhibitor of thrombin [29] . Viewed from a 'cell-based' perspective of rFVIIa function, the microfluidic data support a mechanism for (i) initiation of coagulation (TF or FXIIa) and (ii) the ability to propagate FXa and thrombin generation on the platelet surface (via Table 2 . Clotting potential of severe or moderate haemophilic A or B blood when triggered by the low or high levels of contact activation or extrinsic activation in the presence and absence of recombinant factor VIIa (rFVIIa Rescue indicates return to response levels of healthy blood. Low CTI: 4 lg mL À1 corn trypsin inhibitor; high CTI: 40 lg mL À1 corn trypsin inhibitor.
Mild haemophilic blood (>14-15%) performs without large functional deficit when compared to healthy blood in this assay under conditions of contact or extrinsic activation with reduced sensitivity to added rFVIIa. *This study. Fig. 7 . Systems approach to haemophilic blood clotting. Modulation of the contact pathway (AECTI), tissue factor (TF) Wall , exogenous concentrations of recombinant factor VIIa (rFVIIa) and collagen and its resultant effects on platelet deposition and fibrin formation. Results from perfusion of whole blood (WB) from patients with haemophilia A or B over TF/collagen indicate a crucial role of FIXa/FVIIIa in driving high FXa levels and subsequent thrombin production that produces fibrin under flow. Recombinant FVIIa localization to the platelet surface in combination with contact pathway engagement (FXIIa?FXIa) also drives FXa production, which then results in fibrin formation under flow. Thrombin feedback activation of platelets (not shown) would be expected to reinforce both platelet activation (and procoagulant activity) and platelet deposition to some extent through PAR1/4 signalling.
FIXa/FVIIIa or rFVIIa) to support platelets and especially fibrin deposition (Fig. 7) . In summary, we took a systems approach by modulating the following inputs: contact pathway engagement, the procoagulant surface trigger and exogenous concentrations of rFVIIa. We then explored the impact of these inputs and found distinct changes in platelet deposition and fibrin generation as a function of these inputs (Fig. 7, Table 2 ). Based on this study and our earlier study [24] , endogenous FVII(a) or rFVIIa cannot fully rescue fibrin deposition via the cellular pathway alone in severe haemophilia, unless FXIIa or TF participates. However, the deconvolution of rFVIIa function on platelets in the presence of wall-bound TF requires further study as it is complicated in part by thrombin feedback mechanisms that may cross-enhance the two pathways, as was seen for net thrombin production by rFVIIa and FXIIa in an earlier study [24] .
In conclusion, our microfluidic assay results from WB of FVIII-or FIX-deficient patients indicate a critical role of the intrinsic tenase in driving platelet adhesion and fibrin formation on TF-laden collagen substrates at venous shear rates (Fig. 7) . FVIII/FIXdependent thrombin production on the platelet surface and the subsequent thrombin activation of platelets along with fibrin formation are potent, key pathways in thrombus formation under flow.
